ConforMIS Inc (CFMS) CFO Sells $16,872.91 in Stock
ConforMIS Inc (NASDAQ:CFMS) CFO Paul S. Weiner sold 7,433 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $16,872.91. Following the transaction, the chief financial officer now directly owns 167,116 shares in the company, valued at approximately $379,353.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of ConforMIS Inc (CFMS) traded up $0.07 on Friday, hitting $2.46. 246,700 shares of the stock traded hands, compared to its average volume of 712,257. The firm has a market cap of $108.25, a PE ratio of -1.84 and a beta of 2.21. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.19 and a quick ratio of 5.38. ConforMIS Inc has a 12 month low of $2.21 and a 12 month high of $8.91.
ConforMIS (NASDAQ:CFMS) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.03. The business had revenue of $18.40 million for the quarter, compared to the consensus estimate of $17.55 million. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.31) earnings per share. equities research analysts forecast that ConforMIS Inc will post -1.27 earnings per share for the current fiscal year.
Several brokerages have recently issued reports on CFMS. ValuEngine raised shares of ConforMIS from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. BTIG Research reaffirmed a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. Finally, Zacks Investment Research cut shares of ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $5.54.
Institutional investors have recently added to or reduced their stakes in the company. Platinum Investment Management Ltd. raised its position in shares of ConforMIS by 23.6% in the second quarter. Platinum Investment Management Ltd. now owns 335,156 shares of the medical instruments supplier’s stock valued at $1,437,000 after purchasing an additional 63,900 shares during the period. Ark Investment Management LLC lifted its holdings in ConforMIS by 208.5% during the 2nd quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock worth $825,000 after purchasing an additional 130,009 shares in the last quarter. Bank of New York Mellon Corp increased its stake in ConforMIS by 35.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 171,901 shares of the medical instruments supplier’s stock worth $737,000 after acquiring an additional 45,096 shares during the last quarter. Northern Trust Corp increased its stake in ConforMIS by 15.2% in the 2nd quarter. Northern Trust Corp now owns 454,468 shares of the medical instruments supplier’s stock worth $1,950,000 after acquiring an additional 60,034 shares during the last quarter. Finally, Citadel Advisors LLC increased its stake in ConforMIS by 331.2% in the 3rd quarter. Citadel Advisors LLC now owns 113,972 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 87,540 shares during the last quarter. 35.57% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “ConforMIS Inc (CFMS) CFO Sells $16,872.91 in Stock” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://theolympiareport.com/2017/12/23/conformis-inc-cfms-cfo-sells-16872-91-in-stock-2.html.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.